ARCH Venture Fund VII, L.P.

Average Profitability
<0.0001%
Insider Buys Quantity
2
Insider Buys Sum
$17M
Insider Sells Quantity
9
Insider Sells Sum
$2.92M

Insider Activity of ARCH Venture Fund VII, L.P.

The largest purchase of all time was on 2020-12-22 and amounted to 600000 shares of 908 Devices Inc. for $12M.

The largest sale of all time was on 2019-03-13 and amounted to 84411 share of Syros Pharmaceuticals, Inc. for $666,565.

Biography of ARCH Venture Fund VII, L.P.

No biography is available at this moment.

2020-12-22Purchase908 Devices Inc.
MASS
10 percent owner
600,000
3.8866%
$20.00$12M-31.92%
2019-07-17SaleSyros Pharmaceuticals, Inc.
SYRS
10 percent owner
34,521
0.0825%
$7.70$265,687+4.08%
2019-07-16SaleSyros Pharmaceuticals, Inc.
SYRS
10 percent owner
25,779
0.0622%
$7.81$201,277+3.15%
2019-07-15SaleSyros Pharmaceuticals, Inc.
SYRS
10 percent owner
2,700
0.007%
$8.27$22,316+4.65%
2019-03-14SaleSyros Pharmaceuticals, Inc.
SYRS
10 percent owner
43,000
0.1237%
$8.15$350,441-14.06%
2019-03-13SaleSyros Pharmaceuticals, Inc.
SYRS
10 percent owner
84,411
0.244%
$7.90$666,565-10.75%
2019-03-12SaleSyros Pharmaceuticals, Inc.
SYRS
10 percent owner
40,092
0.1198%
$7.37$295,374-0.96%
2019-03-11SaleSyros Pharmaceuticals, Inc.
SYRS
10 percent owner
44,878
0.1311%
$6.49$291,366+9.88%
2019-03-08SaleSyros Pharmaceuticals, Inc.
SYRS
10 percent owner
84,496
0.2691%
$6.93$585,270+12.42%
2019-03-07SaleSyros Pharmaceuticals, Inc.
SYRS
10 percent owner
35,209
0.1039%
$6.87$242,013+4.86%
2016-07-06PurchaseSyros Pharmaceuticals, Inc.
SYRS
10 percent owner
400,000
1.2619%
$12.50$5M-24.03%
Company
About Prismo.proNewsPrivacy PolicyTerms of ServiceContact Us
Investing Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny Stocks
Stock Tools
Insiders ScreenerStocks ScreenerTop StocksList of All Stocks
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.